Abstract:γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen presentation, which makes them a highly promising effector cell compartment for cancer immunotherapy. Novel γδ T-cell-based immunotherapies, primarily focusing on the two major γδ T-cell subtypes that infiltrate tumors ( i.e. Vδ1 and Vδ2), are being developed. The Vδ1 T-cell subset is enriched in tissues and contains both effector T-cells as well as regulatory T-cells with tumor-promoting potential. Vδ2 T-cells, in contrast, are enriched in circulation and consist of a large, relatively homogeneous, pro-inflammatory effector T-cell subset. Healthy individuals typically harbor in the order of 50-500 million Vγ9Vδ2 T-cells in the peripheral blood alone (1-10% of the total CD3 + T-cell population), which can rapidly expand upon stimulation. The Vγ9Vδ2 T-cell receptor senses intracellular phosphorylated metabolites, which accumulate in cancer cells as a result of mevalonate pathway dysregulation or upon pharmaceutical intervention. Early clinical studies investigating the therapeutic potential of Vγ9Vδ2 T-cells were based on either ex vivo expansion and adoptive transfer or their systemic activation with aminobisphosphonates or synthetic phosphoantigens, either alone or combined with low dose IL-2. Immune-related adverse events (irAE) were generally \mild, but the clinical efficacy of these approaches provided overall limited benefit. In recent years, critical advances have renewed the excitement for the potential of Vγ9Vδ2 T-cells in cancer immunotherapy. Here, we review γδ T-cell-based therapeutic strategies and discuss the prospects of those currently evaluated in clinical studies in cancer patients as well as future therapies that might arise from current promising pre-clinical results.

Landscape of unconventional γδ T cell subsets in cancer

The Microbiota is a Potential Mediator of the Crosstalk Between Γδ T Cells and Tumors

Expansion and Immunological Study of Human Tumor Infiltrating Gamma/Delta T Lymphocytes in vitro<sup>1</sup>

γδ T Cells in the Tumor Microenvironment—Interactions With Other Immune Cells

Effect of γδT Cells in Tumor

From backstage to the spotlight: γδT cells in cancer

The capability of heterogeneous γδ T cells in cancer treatment

Cancer immunotherapy by γδ T cells

γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion

The emerging roles of γδ T cells in cancer immunotherapy

γδ cell-based immunotherapy for cancer

The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy

Human Γδt-Cell Subsets and Their Involvement in Tumor Immunity.

Function of γδ T cells in tumor immunology and their application to cancer therapy

Exploring γδ T cells for use in non-MHC restricted immunotherapy

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future

γδ T cells as critical anti-tumor immune effectors

Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy

In respond to commensal bacteria: γδT cells play a pleiotropic role in tumor immunity

Research Progress of γδT Cells in Tumor Immunotherapy

γδ T cells: a sparkling star for clinical immunotherapy